Please assess the completion status of the following clinical trial:

Trial Title: Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ulcerative colitis of at least 4 months duration~* disease activity index score (Walmsley) \>5 and \</=13~* patients taking no ulcerative colitis relevant medicine, or stable doses of aminosalicylates or maximum 10mg prednisolon daily the last 2 weeks before study entry. They must remain on the same dose throughout the study (6 months).~* stool examination negative for enteric pathogens, clostridium difficile toxin and parasites~Exclusion Criteria:~* ulcerative colitis disease activity index \>13~* symptoms of bowel obstruction~* other serious medical condition~* use of any of the study vaccines during the last two years~* use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first vaccine dose, or planned use during study period~* pregnant or planning to become pregnant~* breastfeeding~* chronic administration of prednisolone more than 10mg per day or steroids of equivalent dose the last 2 weeks before the first vaccine dose~* treatment with anti-tumor necrosis factor within 3 months prior to the first vaccine dose~* use of other immunosuppressants or immune modifying drugs within 30 days prior to the first vaccine dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Vaccination with Vivotif and Dukoral
- 3 (Type: EXPERIMENTAL): Dietary supplement with oats
- 4 (Type: PLACEBO_COMPARATOR): Placebo instead of vaccines No dietary supplement
- 1 (Type: EXPERIMENTAL): Vaccination with Vivotif and Dukoral + dietary supplement with oats.

Based on this trial design, predict the completion outcome and termination type (if applicable).